DP-b99 (D-Pharm).

Abstract	DP-b99 is a derivative of the calcium chelator BAPTA that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft. By March 2003, phase II clinical trials in acute stroke and traumatic brain injury were ongoing.
Authors	Pollen K F Yeung
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 1 Pg. 90-4 (Jan 2004) ISSN: 1472-4472 [Print] England
PMID	14983980 (Publication Type: Journal Article, Review)
Chemical References	DP-b99 Neuroprotective Agents Egtazic Acid
Topics	Animals Brain Ischemia (drug therapy) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Coronary Artery Bypass (adverse effects) Craniocerebral Trauma (drug therapy) Egtazic Acid (analogs & derivatives, chemistry, pharmacokinetics, therapeutic use) Humans Nervous System Diseases (drug therapy, etiology) Neuroprotective Agents (chemistry, pharmacokinetics, therapeutic use) Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!